or intermediate endpoints. For rolling review to be authorized, a clear and scientifically sound rationale must be presented, typically through discussions with regulatory authorities.

In preparation for a rolling review, sponsors must develop a comprehensive Regulatory Strategy Document (RSD) that outlines how data will be submitted in phases. The RSD should include a timeline for data generation, key milestones, and roles and responsibilities of the stakeholders involved in the submission process.

• Define key milestones for data submission
• Prepare the Regulatory Strategy Document
• Engage with regulatory authorities early

Step 2: Developing a Comprehensive Dossier for Submission

Once a rolling review strategy is conceived, the next step is to prepare a detailed dossier that aligns with FDA guidelines. The dossier should cover aspects such as chemistry, manufacturing and controls (CMC), nonclinical data, and clinical efficacy and safety data.

The NDA (New Drug Application) packet remains the primary submission vehicle, and it is critical to assemble data from various development phases nuanced by ICH guidelines. All components must be contained within manageable parts that can be submitted iteratively, making organizational clarity essential.

Key documents to include in the dossier are:

• Clinical Study Reports (CSRs): Detailed results of pivotal studies, including methodology, analysis, and findings.
• Protocol Amendments: Any changes made to the study design that could affect outcomes must be documented.
• Investigational New Drug (IND) Safety Reports: Updates on any safety-related events or findings.

Quality system management should align with Good Clinical Practice (GCP) and be documented meticulously. Ensure that all data integrity guidelines are met, providing transparency in data while ensuring consistent quality management practices throughout the entire lifecycle.

Step 3: Implementing a Robust Quality Management System (QMS)

A robust Quality Management System (QMS) is crucial for overseeing the lifecycle of the rolling review process. The QMS must adhere to applicable regulatory and quality frameworks like ISO 9001:2015 and ICH Q10. This includes risk management plans that ensure proper mitigation of any data uncertainty.

Key elements of an effective QMS include:

• Document Control: Implement a routine for maintaining accurate records of decision-making processes, standards, and change controls.
• Training and Qualification: Establish training protocols for personnel involved in the rolling review to ensure consistent understanding and compliance with regulatory requirements.
• Internal Audits: Conduct audits to evaluate compliance with GCP, ICH guidelines, and any applicable therapy area regulations.

Additionally, during the rolling review process, continuous data monitoring and quality checks must be performed. This can include post-submission quality reviews on submitted documents and data. These steps ensure the long-term sustainability of devices and therapies while meeting established criteria set forth by regulatory authorities.

Step 4: Navigating the Submission Process

Once the dossier is complete and the QMS is in place, navigating the submission process is the next pivotal phase. Submissions must be electronically formatted in eCTD format as per FDA specifications, ensuring accuracy and completeness in every module. The FDA provides guidelines and a detailed checklist to prepare for a successful eCTD submission.

As submissions are divided into parts, it is crucial to define what information is included in each submission and document the rationale for any lacked data. Each submission should also include:

• Cover Letter: A general overview of the submission, mentioning what is included and what additional data will be provided in subsequent reviews.
• Summary of Clinical Efficacy: A narrative synthesis of clinical findings documenting the therapy’s effectiveness and safety profile to-date.

Engaging with the FDA throughout the submission process is encouraged. Sponsors can request pre-submission meetings to clarify expectations and requirements, and address any questions. Real-time communication channels are especially vital during rolling reviews as data submission timelines and expectations evolve over the course of the review cycle.

Step 5: Managing Review Outcomes and Post-Approval Commitments

Following the submission, the FDA will review each data package in a timely manner, ideally providing feedback on the submissions in the context of the overall progression of the rolling review. That being said, maintaining an ongoing dialogue with the agency throughout the review process will enhance understanding and response to any potential review outcomes.

If the review is successful, the next step involves implementing post-approval commitments. Post-approval commitments may include:

• Phase IV Trials: Conduct studies post-approval to confirm safety and efficacy.
• Risk Evaluation and Mitigation Strategies (REMS): Develop risk communication strategies to ensure that adverse events are reported and managed effectively.

These commitments must be meticulously documented, with regular updates provided to the FDA regarding the progress of studies funded as post-approval commitments. This establishes a reliable feedback loop with the agency, strengthening the ongoing lifecycle management process.

Conclusion: Best Practices for Success in Rolling Review

Successfully managing a rolling review requires a synthesis of regulatory knowledge, effective communication and a commitment to quality throughout the data submission lifecycle. By following the outlined steps—establishing a clear understanding of rolling review, preparing a robust submission dossier, implementing an effective QMS, navigating the submission process meticulously, and managing both review outcomes and post-approval commitments—companies can position themselves for success.

Organizations must also be relentless about compliance with all requirements and guidelines laid down by the FDA, ensuring that they remain vigilant in their responsibilities under the rolling review process. For those involved in FDA lifecycle management consulting, practical application of the regulatory concepts covered in this tutorial will foster a culture of quality and safety while facilitating the expedited access to important therapies for patients in need.